Post by
subaru1i on May 01, 2024 6:34pm
505(b)2, 'new indication', FDA submission/pre DEA: viral
anti-inflammatory? Hopefully it is because the U.S. is at the precipice of a zoonotic pandemic, something the country's debt load will find extremely difficult to burden.
Let's wait and see if LABS saw the writing on the wall w.r.t. to Disease X because as well, their healh care system could barely cope with COVID's inflammatory effects on the human respiratory system.
Was it coincidence the DEA suddenly decided to reschedule cannabis from 3 to 1 in the face of 38+ states having dairy and beef cattle infected with the avian virus???